Mechanistic description
The debate supports carrying forward APOE4 lipid dysregulation and synaptic phagocytosis as early drivers of AD pathology only if a proximal endpoint changes before the late outcome. The decisive validation path is: compare APOE4-to-APOE3 correction in neuron-microglia-astrocyte co-cultures with amyloid, lipid, and synapse engulfment readouts.
Mechanism / pathway
- APOE
- neurodegeneration
Evidence for (1)
Preregistered claim: APOE4-driven lipid dysregulation and synaptic phagocytosis drive AD; converting APOE4 to APOE3 reduces amyloid and restores synaptic function
Evidence against (1)
APOE genotype affects many cell types, so target conversion could rescue biomarkers without proving synaptic causality
Evidence matrix
Supporting
- Preregistered claim: APOE4-driven lipid dysregulation and synaptic phagocytosis drive AD; converting APOE4 to APOE3 reduces amyloid and restores synaptic function AD-MASTER-PLAN-APOE-20260428030754
Contradicting
- APOE genotype affects many cell types, so target conversion could rescue biomarkers without proving synaptic causality AD-MASTER-PLAN-APOE-20260428030754
Cite this hypothesis
Cite this hypothesis
etl-backfill (2026). APOE4 lipid dysregulation and synaptic phagocytosis as early drivers of AD path…. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-7a3aba26c2
@misc{scidex_hypothesis_h7a3aba2,
title = {APOE4 lipid dysregulation and synaptic phagocytosis as early drivers of AD path…},
author = {etl-backfill},
year = {2026},
howpublished = {SciDEX hypothesis},
url = {https://prism.scidex.ai/hypotheses/h-7a3aba26c2},
note = {SciDEX artifact hypothesis:h-7a3aba26c2}
}